Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Histamine Phosphate

Copy Product Info
🥰Excellent
Catalog No. T6535Cas No. 51-74-1
Alias Histamine diphosphate, Histamine acid phosphate

Histamine phosphate is a potent agonist of histamine receptors and a vasodilatory neurotransmitter. It can activate nitric oxide synthase and is commonly used to induce gastric ulcer models.

Histamine Phosphate

Histamine Phosphate

Copy Product Info
🥰Excellent
Catalog No. T6535Alias Histamine diphosphate, Histamine acid phosphateCas No. 51-74-1
Histamine phosphate is a potent agonist of histamine receptors and a vasodilatory neurotransmitter. It can activate nitric oxide synthase and is commonly used to induce gastric ulcer models.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
100 mg$29In Stock-
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>99.99%
Appearance:solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Histamine phosphate is a potent agonist of histamine receptors and a vasodilatory neurotransmitter. It can activate nitric oxide synthase and is commonly used to induce gastric ulcer models.
In vitro
Histamine (10 μM) gives a larger inositol monophosphate accumulation in bovine adrenal chromaffin cells. Histamine (10 μM) stimulates the level of radioactivity into the InsP3-containing fraction in bovine adrenal chromaffin cells. Histamine (100 μM) stimulates incorporation into the InsP3-containing eluate in a less extent than for angiotensin I1 and bradykinin. [1]
In vivo
Histamine phosphate (0.025 mg/kg) produces a mean increase in basilar blood flow of 145% of control in dogs. Histamine phosphate produces considerable increases in basilar blood flow as well as a decrease in femoral arterial blood pressure in dogs when injected intravenously and measured with an electromagnetic flow transducer. [2] Histamine phosphate (4 μg/kg) causes lymph flow to increase from 6.0 to 27.0 (SEM) ml/h in unanesthetized sheep. Histamine phosphate (4 μg/kg) also causes increases in lung water, pulmonary vascular resistance, arterial PCO2, pH, and hematocrit, and decreases in cardiac output and arterial PO2 in unanesthetized sheep. [3] Histamine phosphate (8.3 mg/kg/min) causes no significant change in pulmonary lymph flow (QL) or protein concentration (CL) in anesthetized open-chested dogs, however, both are increased after alloxan. Histamine phosphate (8.3 mg/kg/min) also causes no significant change in the pulmonary capillary membrane filtration coefficient (Kf) and the maximum capillary pressure (PCcritical) in anesthetized open-chested dogs. [4] Histamine phosphate (50 mg/kg) produces a pronounced rise in acid secretion but the output of pepsin remained unchanged in the unanaesthetized intact rat. Histamine phosphate (50 mg/kg) produces maximal stimulation of gastric acid secretion and is free from toxic effects in the unanaesthetized intact rat. [5]
Disease Modeling Protocol
Duodenal Ulcer Model
  • Modeling Mechanism:

    Histamine Phosphate needs to act synergistically with indomethacin to induce a rat model of duodenal ulcer. It strongly promotes gastric acid secretion by binding to H₂ receptors on parietal cells, and synergizes with indomethacin to inhibit duodenal bicarbonate secretion and weaken mucosal defense function, resulting in a sharp increase in acid load in the duodenum, damage to mucosal epithelial cells, and ultimately ulcer formation.

  • Related Products:

    Histamine (T0965)

  • Modeling Method:

    Experimental Subject:

    Rats, Donryu, Male, Body weight 230-260g, Fasted for 24 hours

    Dosage and Administration Route:

    ① Core modeling: Indomethacin (5 mg/kg) suspended in saline with a trace of Tween 80 via subcutaneous injection (0.5 ml/100g body weight); 30 minutes later, histamine dihydrochloride (40 mg/kg) dissolved in 10% gelatin via subcutaneous injection, 3 doses total with 2.5-hour intervals between doses;
    ② Control treatment: Single subcutaneous injection of indomethacin (5 mg/kg) alone, histamine (40 mg/kg, 3 doses with 2.5-hour intervals) alone, or isovolumetric vehicle (saline with Tween 80/10% gelatin);
    ③ Intervention validation (optional): Cimetidine (3-100 mg/kg) suspended in saline via oral gavage; 16,16-dimethylprostaglandin E₂ (dmPGE₂, 3-30 μg/kg) first dissolved in absolute ethanol then diluted with saline via oral gavage; both administered 30 minutes prior to indomethacin injection

    Dosing Frequency and Duration Model:

    Single indomethacin injection+3 histamine injections (2.5-hour intervals)

  • Validation:

    1. Pathological indicators: 1-2 round ulcer lesions (area 9.8±1.4 mm²) in the proximal duodenum with 100% ulcer incidence; a few scattered lesions in the gastric corpus and antrum; 30%-40% of duodenal ulcers penetrated the muscularis mucosae, and a single large round ulcer was still visible after 32 hours; no ulcer formation with indomethacin or histamine alone; 2. Biochemical indicators: Gastric acid secretion significantly increased compared with the control group (peak value 23-25 μEq/15 min for histamine alone, >30 μEq/15 min for combined administration); duodenal basal HCO₃⁻ secretion slightly inhibited, and acid-stimulated HCO₃⁻ secretion completely blocked; 3. Drug intervention validation: Cimetidine (≥10 mg/kg) dose-dependently inhibited ulcer formation and significantly reduced gastric acid secretion; dmPGE₂ (3-30 μg/kg) dose-dependently reduced the area of duodenal and antral ulcers and significantly increased HCO₃⁻ secretion; both reduced the acid load in the duodenum (peak value 24.2±1.6 μEq/30 min in the cimetidine group, 35.1±4.8 μEq/30 min in the dmPGE₂ group).

*Precautions: Subjects were euthanized and sampled 8 hours after indomethacin administration; some animals were normally fed for 24 hours after the last histamine injection and sampled 32 hours after indomethacin administration.

*References:Takeuchi K,et,al. A new model of duodenal ulcers induced in rats by indomethacin plus histamine. Gastroenterology. 1986 Mar;90(3):636-45.

SynonymsHistamine diphosphate, Histamine acid phosphate
Chemical Properties
Molecular Weight307.14
FormulaC5H9N·2H3O4P
Cas No.51-74-1
SmilesO.OP(O)(O)=O.OP(O)(O)=O.NCCc1c[nH]cn1
Relative Density.no data available
Storage & Solubility Information
StoragePowder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
H2O: 10 mM, Sonication is recommended.
DMSO: Insoluble
Solution Preparation Table
H2O
1mg5mg10mg50mg
1 mM3.2558 mL16.2792 mL32.5584 mL162.7922 mL
5 mM0.6512 mL3.2558 mL6.5117 mL32.5584 mL
10 mM0.3256 mL1.6279 mL3.2558 mL16.2792 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Histamine Phosphate | purchase Histamine Phosphate | Histamine Phosphate cost | order Histamine Phosphate | Histamine Phosphate chemical structure | Histamine Phosphate in vivo | Histamine Phosphate in vitro | Histamine Phosphate formula | Histamine Phosphate molecular weight